John Kurek

John Kurek has an extensive work experience history in the biotechnology and venture capital sectors. John currently holds the position of Investment Manager at Uniseed, Australia's longest-running venture fund. In this role, they support researchers from partner research organizations in turning their ideas into products and services.

In addition to their role at Uniseed, John Kurek also serves as a Non-Executive Director in various biotechnology companies. These include Currus Biologics Pty Ltd, where they contribute to the development of a proprietary bi-specific antibody for improving CAR-T cell therapy. John also serves as a Non-Executive Director at Ena Respiratory Pty Ltd, Certa Therapeutics, Kinoxis Therapeutics Pty Ltd, EXONATE LIMITED, Axelia Oncology Pty Ltd, OccuRx, and Q-Sera Pty Ltd. At Q-Sera Pty Ltd, they are involved in the development of blood collection tubes that rapidly produce high-quality serum.

Additionally, John Kurek has previous experience as a Non-Executive Director at Spinifex Pharmaceuticals Pty Ltd, a biotechnology start-up that successfully completed a Phase-2a clinical trial and was later acquired by Novartis.

Overall, John Kurek has a proven track record in supporting innovation, commercialization, and corporate governance within the biotechnology industry.

John Kurek's education history includes a BSc (Hon) in Biochemistry from Monash University, which they received between 1985 and 1988. John then pursued a PhD in Neuroscience at the University of Melbourne from 1993 to 1996. Following that, they completed a Graduate Diploma in Drug Evaluation & Pharmaceutical Science at the University of Melbourne from 1997 to 1998. In 2007, John attended the Australian Institute of Company Directors, where they completed a Graduate, Company Directors Course. There is no information provided regarding John's education before 1984.